Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial

BACKGROUND: Needle-free delivery improves the immunogenicity of DNA vaccines but is also associated with more local reactogenicity. Here we report the first comparison of Biojector and needle administration of a candidate rAd5 HIV vaccine. METHODS: Thirty-one adults, 18–55 years, 20 naive and 11 pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarwar, Uzma N., Novik, Laura, Enama, Mary E., Plummer, Sarah A., Koup, Richard A., Nason, Martha C., Bailer, Robert T., McDermott, Adrian B., Roederer, Mario, Mascola, John R., Ledgerwood, Julie E., Graham, Barney S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179264/
https://www.ncbi.nlm.nih.gov/pubmed/25264782
http://dx.doi.org/10.1371/journal.pone.0106240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179264/
https://www.ncbi.nlm.nih.gov/pubmed/25264782
http://dx.doi.org/10.1371/journal.pone.0106240

Ejemplares similares